For liver enzymes, we reported a significant reduction only in ALP levels after 6 and 12 months from baseline, with means of 7.25 and 5.53 IU/L, respectively; these reductions were also reported in one meta-analysis study involving 12 studies with GLP-1RA arms and 677 subjects that showed that treatment with GLP-1RA reduced ALT, gamma-glutamyl transferase (GGT), and ALP with no change in AST level, leading to the conclusion that GLP-1RA treatment significantly reduces liver enzymes in patients with NAFLD [21]. Here, GPT is linked to metabolic dysfunction-associated steatotic liver disease.